The following is a summary of the Knight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call Transcript:

Financial Performance:

• Knight Therapeutics reported record-high revenues for Q4 2024, totaling over $365 million, driven by 75% of total revenues coming from key promoted products with a three-year CAGR of over 30%.

• Adjusted EBITDA for the fiscal year was approximately $58 million.

• Q4 revenue increased by $6 million or 6% year-over-year, with constant currency revenues up by $29 million or 9%.

• Gross margin for 2024 was reported at 47%, slightly down from the previous year due to product mix.

Business Progress:

• Expanded neurology portfolio with licenses for Crexont from Amneal and Jornay PM from Collegium across all territories.

• Enhanced partnerships, including a strengthened relationship with Helsinn in Latin America.

• Advanced regulatory submissions for four innovative products: Qelbree, TAVALISSE, Minjuvi, and Pemazyre in multiple territories.

• Achieved regulatory approvals for several products, including Minjuvi and TAVALISSE in Mexico.

• Launched Bijuva and Imvexxy in Canada, and Minjuvi in Brazil.

• Acquired all assets of Paladin, adding $70 million in revenues and expanding the Canadian business.

Opportunities:

• Continued growth driven by Knight's expanding product pipeline, expecting product launches to generate peak sales of over $150 million.

• New contract signed with Brazil's Ministry of Health expected to deliver approximately $22.4 million in 2025, building upon existing government relationships and expanding market presence.

• The acquisition of Paladin enhances Knight's Canadian business significantly, providing stability and cash flow to fuel further growth in Canada and Latin America.

Risks:

• No explicit risks detected.

More details: KNIGHT THERAPEUTICS INC IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.